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FSGS constitutes the main cause of nephrotic syndrome in some regions of the world, including the United States and Canada.[@bib1], [@bib2], [@bib3] It is also the most common primary glomerular disease leading to end-stage renal disease in the United States.[@bib4], [@bib5]

The goal of therapy in FSGS is to induce a complete or partial remission of proteinuria with long-term preservation of renal function. Both complete and partial remission have been associated with improved long-term survival.[@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13]

High-dose corticosteroids remain the first-line therapy for primary FSGS when associated with the nephrotic syndrome,[@bib14] with response rates varying from 42% to 62%.[@bib9], [@bib10], [@bib11], [@bib12], [@bib13] Based on the observation that prolonged corticosteroid courses (\>16 weeks) are associated with a better response,[@bib10] current guidelines recommend treatment with high-dose corticosteroids (prednisone 1 mg/kg per day and up to 80 mg/d) for 4 to 16 weeks with subsequent slow tapering over a few months. Steroid resistance is defined as little or no reduction in proteinuria after 12 to 16 weeks of treatment.[@bib14]

CNIs as a first-line therapy are reserved for patients at high risk for steroid-induced complications, such as those with diabetes, uncontrolled psychiatric disorders, or severe osteoporosis.[@bib14] Recently, FSGS CNI first-line therapy was reported to be numerically superior to glucocorticoids in preventing ESRD in an observational cohort[@bib15]; however, the authors provided no data on response rates, number of relapses, and glucocorticoid exposure. Two additional small reports have reported a response in 6 of 6 and in 6 of 7 patients treated with first-line tacrolimus[@bib16] or cyclosporine,[@bib17] respectively.

Reduction of corticosteroid exposure is currently a relevant focus in the management of glomerular diseases, given that high-dose corticosteroids are known to be associated with a multiplicity of adverse effects, especially when prescribed in prolonged courses and high doses, as is the case for FSGS.[@bib18], [@bib19]

In the last few years, our center started managing patients with primary FSGS with CNI associated with low-dose corticosteroids as a first-line therapy, with the goal of reducing corticosteroid exposure. The aim of this study was to compare response to therapy and cumulative corticosteroid exposure between patients with first-line CNI, those with high-dose corticosteroids, and those with CNI added for steroid-resistant disease.

Methods {#sec1}
=======

Subjects {#sec1.1}
--------

In this retrospective cohort study, we reviewed the charts of all patients with biopsy-proven primary FSGS who were seen at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City from 2007 to 2014 and who completed at least 24 months of follow-up.

Primary FSGS was defined by clinical and histopathological criteria. Clinical criteria included presentation with nephrotic syndrome and absence of a recognized secondary etiology (e.g., infectious agents, drugs, morbid obesity, etc.). Histopathological criteria included diffuse foot process effacement \>80% by electron microscopy (available in 29 patients) and absence of secondary FSGS features by light microscopy examination.

Treatment Groups {#sec1.2}
----------------

Patients were divided into 3 treatment groups: high-dose prednisone, first-line CNI plus low-dose prednisone (first-line CNI), and first-line high-dose prednisone plus added CNI rescue for steroid-resistant disease (rescue CNI). Patients treated with high-dose prednisone received 0.8 to 1.0 mg/kg prednisone for at least 12 weeks with subsequent tapering. The first-line CNI group received treatment with either cyclosporine or tacrolimus, aiming for serum levels between 100 and 180 ng/ml and between 5 and 7 ng/ml, respectively, with 0.10 to 0.15 mg/kg per day of prednisone. The rescue CNI group received 0.8 to 1.0 mg/kg prednisone for 12 weeks, the time at which proteinuria was evaluated and, if there was a reduction of \<25%, a CNI was added to the therapy.

Outcomes {#sec1.3}
--------

The 3 groups were evaluated for cumulative prednisone dose, complete remission, partial remission, time to relapse, progression to end-stage renal disease (ESRD), and adverse events as registered in the patient records.

Complete remission (CR) was defined as stable renal function (no less than 15% of baseline estimated glomerular filtration rate) plus 24-hour urine protein-to-creatinine ratio \<0.3 g/g. Partial remission (PR) was defined as stable renal function plus 50% reduction of proteinuria to subnephrotic range. Relapse was defined as doubling of the previous urine protein-to-creatinine ratio to a proteinuria \>3.5 g/g observed on 2 consecutive visits, with or without features of the nephrotic syndrome. Doubling of serum creatinine was defined as doubling of the lowest serum creatinine value achieved during the first 6 months of therapy. End-stage renal disease was defined as estimated glomerular filtration rate of \<10 ml/min or requirement of renal replacement therapy.

Predictors {#sec1.4}
----------

We obtained data on patients' clinical courses. Baseline evaluation was considered at the time of the diagnostic kidney biopsy. Data collected included age, gender, body mass index, mean arterial pressure, serum creatinine and proteinuria (quantified by 24-hour collections) at baseline and every 6 months during follow-up, hemoglobin, platelets, hematuria (defined as \>5 erythrocytes per high-power field), serum albumin, triglycerides, cholesterol, and serum complement C3 and C4.

Histopathological parameters included percentage of global/segmental sclerosis, mesangial expansion, interstitial fibrosis, tubular atrophy, and vascular and immunofluorescence findings. A chronicity score was calculated based on a recently proposed scale[@bib20] that considers total glomerulosclerosis (global plus segmental), interstitial fibrosis, tubular atrophy, and intimal thickening. Treatment data were collected throughout the duration of each patient's clinical course.

Statistical Analysis {#sec1.5}
--------------------

Data distribution was evaluated by the Shapiro−Wilk test. Baseline data are described as number and relative frequencies or as median and interquartile range, as appropriate. For baseline comparisons, the χ^2^, Fisher exact, or Kruskal−Wallis test was used as appropriate. For response to therapy outcomes (complete/partial remission), patients were censored at 24 months of follow-up and compared by log-rank test for time to outcome. For end-stage renal disease, we used Cox proportional hazards models over the entire duration of follow-up. To obtain independent predictors for outcome, we first used a univariate model, and all variables with *P* \< 0.100 were included in the final multivariate analysis, which included age, gender, baseline creatinine and proteinuria, response to therapy, and chronicity score.

All analyses were performed with JMP Pro 12.0 Statistical Software (SAS Institute Inc., Cary, NC) and GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA). Statistical significance was considered with a *P* value \<0.05.

Results {#sec2}
=======

From 2007 to 2014, a total of 112 patients were diagnosed with FSGS. Of these patients, 70 (63%) were classified as having primary FSGS. Among them, 4 patients had nonnephrotic proteinuria and were excluded. A total of 66 patients were selected for the study and divided into 3 treatment groups ([Figure 1](#fig1){ref-type="fig"}): high-dose prednisone (n = 39), first-line CNI (n = 11), and rescue CNI (n = 16). The median follow-up for this cohort was 51 months (IQR = 30−77).Figure 1Patient flowchart.

Baseline Characteristics {#sec2.1}
------------------------

Baseline characteristics are shown in [Table 1](#tbl1){ref-type="table"}. Patients in the high-dose prednisone group were older (*P* = 0.041), but there were no significant differences in any other variables such as proteinuria, serum creatinine, or coexistence of acute kidney injury at presentation. Histopathological characteristics are shown in [Table 2](#tbl2){ref-type="table"}. There were no differences in the FSGS subtypes according to the Columbia classification, the percentage of sclerosis, interstitial fibrosis, or tubular atrophy.Table 1Characteristics of the studied cohortVariableHigh-dose prednisone\
n = 39First-line CNI\
n = 11Rescue CNI\
n = 16*P* valueAge, yr37 (24--46)23 (18--31)29 (24--41)0.041Male, n (%)21 (53.8)3 (36.4)8 (50.0)0.592Body mass index, kg/m^2^25.6 (23.0--28.7)28.3 (24.7--33.5)26.9 (24.4--31.4)0.257Mean arterial pressure, mm Hg97 (87--107)92 (83--103)98 (91--103)0.669Hemoglobin, g/dl14.9 (13.0--16.9)13.7 (12.4--16.9)15.4 (14.4--16.5)0.508Platelets, per mm^3^287 (214--376)304 (216--370)310 (268--381)0.790Serum creatinine, mg/dl1.3 (0.7--1.8)1.3 (0.6--1.7)1.0 (0.6--1.4)0.639Estimated GFR, ml/min per 1.73 m^2^60 (41--115)58 (48--122)79 (66--112)0.495Proteinuria, g/24 h4.9 (3.5--8.0)7.4 (3.6--11.9)6.7 (3.8--11.0)0.449Protein to creatinine ratio, g/g3.7 (3.2--7.3)4.9 (3.7--7.6)5.8 (3.6--8.7)0.359Protein to creatinine ratio at CNI start, g/g[a](#tbl1fna){ref-type="table-fn"}---4.9 (3.7--7.6)5.7 (4.1--9.3)0.544Serum albumin, g/dl2.6 (1.6--2.9)2.9 (2.3--3.3)2.4 (1.0--2.8)0.072Triglycerides, mg/dl261 (211--329)314 (201--341)270 (219--316)0.927Cholesterol, mg/dl262 (198--338)282 (212--341)325 (253--483)0.188Acute kidney injury, n (%)3 (7.7)1 (9.1)1 (6.3)0.962[^1][^2]Table 2Histological parameters of the cohortVariableHigh-dose prednisone\
n = 39First-line CNI\
n = 11Rescue CNI\
n = 16*P* valueColumbia classification0.233 NOS18 (45.2)4 (36.4)4 (25.0)0.360 Tip6 (15.4)2 (18.2)5 (31.3)0.422 Perihiliar11 (28.2)4 (36.4)3 (18.8)0.635 Cellular4 (25.6)1 (9.1)4 (25.0)0.367Global sclerosis (%)10 (0--22)14 (0--33)3 (0--16)0.358Segmental sclerosis (%)17 (4--30)14 (7--27)13 (7--28)0.898Interstitial fibrosis (%)20 (10--40)10 (10--50)13 (10--38)0.741Tubular atrophy (%)20 (10--40)10 (5--50)13 (6--38)0.749Vascular subintimal fibrosis17 (43.6)3 (27.3)6 (37.5)0.610Vascular medial hyperplasia12 (30.8)2 (18.2)5 (31.3)0.696[^3]

Treatment and Corticosteroid Exposure {#sec2.2}
-------------------------------------

There were no differences in adjunctive therapies (angiotensin-converting enzyme inhibitors, statins) among the 3 groups ([Table 3](#tbl3){ref-type="table"}). Median average cyclosporine or tacrolimus serum levels were 134 ng/ml (IQR = 92−186 ng/ml) and 5.2 ng/ml (IQR = 4.0−7.9 ng/ml), respectively, in the first-line CNI group, and 128 ng/ml (IQR = 92−172 ng/ml) and 5.8 ng/ml (IQR = 4.4−7.3 ng/ml), respectively, in the rescue-CNI group (*P* = 0.698 and *P* = 0.771). The total duration under CNI treatment was 12 months (6−16 months) and 16 months (9−25 months) in the first-line CNI and rescue CNI group, respectively.Table 3Immunosuppression and adjunctive treatmentVariableHigh-dose prednisone\
n = 39First-line CNI\
n = 11Rescue CNI\
n = 16*P* valuePrednisone Months on prednisone13 (7--22)8 (6--12)24 (12--28)\<0.001 Cumulative prednisone, g9.3 (7.5--12.5)2.5 (1.8--3.1)13.8 (9.2--15.8)\<0.001 Cumulative prednisone, mg/kg134 (112--180)36 (26--39)177 (145--209)\<0.001 Months to taper \<10 mg7 (6--12)6 (4--7)11 (6--18)0.003Calcineurin inhibitor Tacrolimus---5 (45.5)8 (50.0)0.816 Avg plasma level, ng/dl---5.2 (4.0--7.9)5.8 (4.4--7.3)0.698 Cyclosporine---6 (54.5)8 (50.0)0.816 Avg plasma level, ng/dl---134 (92--186)128 (92--172)0.771 Months on CNI---12 (6--16)16 (9--25)0.174Adjunctive treatment RAAS blockade33 (84.6)9 (81.8)15 (93.8)0.596 Statins21 (53.8)5 (45.5)10 (62.5)0.676[^4]

Cumulative doses of prednisone in the high-dose corticosteroid group were 9.3g (IQR = 7.5−12.5g) compared to 2.5 g (IQR = 1.82−3.12g) in the first-line CNI with low-dose corticosteroid group and 1.8 g (IQR = 9.2−15.8g) in the rescue CNI group, respectively (*P* \< 0.001). This was also reflected in the tapering months to a prednisone dose \<10 mg: 7 months (IQR = 6−12 months) in the high-dose prednisone group, 6 months (IQR = 4−7 months) in the first-line CNI group, and 11 months (IQR = 6−18 months) in the rescue CNI group (*P* \< 0.001). The total duration of prednisone exposure was 13 months (min 7, max 22 months), 8 months (min 6, max 12 months), and 24 months (min 12, max 28 months) for the high-dose prednisone, first-line CNI, and rescue CNI groups, respectively.

Treatment Outcomes {#sec2.3}
------------------

Response to treatment (either complete or partial response) was censored at 24 months from the start of therapy. At this point in time, a response to treatment was observed in 30 (76.9%), 8 (72.7%), and 14 (87.5%) patients in the high-dose prednisone, first-line CNI, and rescue CNI groups, respectively ([Figure 2](#fig2){ref-type="fig"}). Complete remission was observed in 19 (48.7%), 4 (36.4%), and 5 (31.3%) patients in the high-dose prednisone, first-line CNI, and rescue CNI groups ([Figure 2](#fig2){ref-type="fig"}), whereas partial remission occurred in 11 (28.2%), 4 (36.4%), and 9 (56.3%) patients, respectively. The individual course of proteinuria and estimated glomerular filtration rate from patients in the first-line CNI group is shown in [Figure 3](#fig3){ref-type="fig"}.Figure 2(a) Complete remission and (b) response to therapy.Figure 3(a) Individual 24-hour urine protein-to-creatinine ratio and (b) estimated glomerular filtration rate in the first-line calcineurin inhibitor (CNI) group. Continuous lines represent patients who responded to therapy; dotted lines, patients with resistant disease; dashed lines, patients with initial response followed by relapse; stars, patients who progressed to end-stage renal disease.

The median time to first response to therapy was 2 (IQR = 1−10 months), 2 (IQR = 1−4 months), and 4 (IQR = 3−7 months) months after the start of therapy in the high-dose prednisone, first-line CNI, and rescue CNI groups, respectively (log-rank test *P* = 0.901).

Among the first-line CNI group, there were no differences in response to therapy between cyclosporine-treated patients (2 complete and 2 partial responses) and tacrolimus-treated patients (2 complete and 2 partial responses).

Relapses {#sec2.4}
--------

A total of 26 (47.3%) relapses occurred in 55 patients who responded to therapy during a median of 25 months (12−46 months) time-at−risk of relapse. The incidence of relapse was 48.4%, 44.4%, and 46.7% in the high-dose prednisone, first-line CNI, and rescue CNI groups, respectively ([Figure 4](#fig4){ref-type="fig"}). There were no differences in time to relapse among the groups (*P* = 0.548).Figure 4Renal (a) survival and (b) disease relapses. CNI, calcineurin inhibitor; PDN, prednisone.

Renal Function {#sec2.5}
--------------

There were no differences in the estimated glomerular filtration rate slope in the first 2 years among the groups: high-dose prednisone, −1.5 (−5.1 to +8.9) ml/min per year; first-line CNI, −4.1 (−17.1 to +16.5) ml/min per year; and rescue CNI, −3.0 (−14.0 to +23.9) ml/min per year (*P* = 0.496). The 5-year renal survival in the whole cohort was 82.4%. A total of 5 (12.8%), 2 (18.2%), and 2 (12.5%) patients doubled their serum creatinine, whereas 3 (7.7%), 2 (18.2%), and 1 (6.3%) progressed to ESRD ([Figure 4](#fig4){ref-type="fig"}). The independent renal survival predictors in the Cox multivariate model ([Table 4](#tbl4){ref-type="table"}) were the presentation proteinuria (hazard ratio \[HR\] = 1.26, 95% confidence interval \[CI\] = 1.05−1.51), chronicity score of the diagnostic biopsy (HR = 1.56, 95% CI = 1.05−2.31), and a complete response to therapy (HR = 0.02, 95% CI = 0.01−0.21).Table 4Cox regression analysis for factors associated with progression to end-stage renal diseaseVariableUnivariateMultivariateHR95% CI*P* valueHR95% CI*P* valueAge, per yr0.9790.934--1.0260.373---------Male gender, versus female0.5880.176--1.9670.389---------Creatinine, per mg/dl1.6221.064--2.4740.025---------Proteinuria, per g/g1.1110.992--1.2440.0701.2591.052--1.5070.012Chronicity score, per point1.5101.122--2.0330.0071.5581.052--2.3050.027Response to treatment No response1.000RefRef1.000RefRef Partial response0.2140.060--0.7680.0180.3560.077--1.6520.187 Complete response0.0260.003--0.2200.0010.0230.001--0.2120.002[^5]

Adverse Events {#sec2.6}
--------------

All the adverse events reported during the first 36 months of follow-up are shown in [Table 5](#tbl5){ref-type="table"}. There were no differences in serious adverse events leading to hospitalization. The number of total infectious events not requiring hospitalization was higher but not statistically significant in the high-dose prednisone group. Renal events as a group, including acute kidney injury and uncontrolled blood pressure, were more frequent in the CNI-first (*P* = 0.0928) and rescue CNI (*P* = 0.0266) groups. Ophthalmic events were observed exclusively in the high-prednisone group.Table 5Adverse events reported during treatment and follow-upVariableSteroids\
n = 39CNI first\
n = 11Rescue CNI\
n = 16Events requiring hospitalization8 (20.5)2 (18.2)5 (31.3) Pneumonia4 (10.3)1 (9.0)1 (6.3) Bacteremia1 (2.6)1 (9.0)2 (12.5) Cytomegalovirus colitis1 (2.6)------ Acute cholecystitis1 (2.6)---1 (6.3) Acute cerebrovascular event------1 (6.3) Upper GI hemorrhage1 (2.6)------Infectious events (not hospitalized)18 (46.2)3 (27.3)4 (25.0) Upper respiratory tract infection10 (25.6)2 (18.2)2 (12.5) Acute diarrhea4 (10.3)1 (9.0)1 (6.3) Cellulitis3 (7.7)---1 (6.3) Oral candidiasis1 (2.6)------Renal events Acute kidney injury4 (10.3)1 (9.0)4 (25.0) Uncontrolled blood pressure1 (2.6)3 (27.3)3 (18.8)Metabolic events Weight gain \>10% baseline3 (7.7)1 (9.0)1 (6.3) Exogenous Cushing features5 (12.8)1 (9.0)3 (18.8) Secondary diabetes1 (2.6)---1 (6.3)Ophthalmic events Cataract1 (2.6)------ Glaucoma1 (2.6)------Others Acidopeptic symptoms4 (10.3)1 (9.0)3 (18.8) Psychiatric symptoms[a](#tbl5fna){ref-type="table-fn"}5 (12.8)---2 (12.5) Inferior vena cava thrombosis1 (2.6)------[^6][^7]

Discussion {#sec3}
==========

Calcineurin inhibitor use in FSGS treatment has been reserved mainly for steroid-resistant patients, whereas first-line therapy has scarcely been studied. Here we report a similar efficacy of a first-line CNI approach in terms of response to therapy compared to a high-dose prednisone regimen. Furthermore, the first-line CNI therapy was associated with 4 times lower exposure to corticosteroids and a relapse rate similar to that associated with high-dose corticosteroid therapy.

Focal and segmental glomerulosclerosis remains the most common nephrotic syndrome etiology in many countries, comprising close to 40% of cases in adults.[@bib1], [@bib21] However, evidence for treatment proceeds from small randomized controlled trials[@bib8], [@bib22], [@bib23], [@bib24] and observational studies.[@bib6], [@bib10], [@bib12], [@bib13], [@bib15], [@bib25], [@bib26], [@bib27] Prolonged courses of treatment, based mainly on high-dose corticosteroids (1 mg/kg for 8−16 weeks) have resulted in response rates that range from 40% to 70% of patients; however, steroid exposure from currently recommended regimens[@bib14] remains among the highest for primary glomerulonephritis with the consequent risk for development of steroid adverse events.[@bib18], [@bib19]

A recent focus in the management of glomerular diseases is the decrease in steroid exposure. Here we showed that a CNI-first approach decreases prednisone exposure up to 4 times with similar rates of response to treatment. A previous report by Laurin *et al.*[@bib15] suggested that a CNI-first approach is effective in preventing progression to ESRD. Small reports have shown a partial response in 6 of 6 patients treated with tacrolimus alone[@bib16] and in 6 of 7 patients treated with cyclosporine combined with steroids.[@bib17] We observed a response rate of 73% with this approach and complete remission rates of 36%. These numbers are relatively high, which may relate to the young age of our cohort.

The prevalence of steroid resistance has been estimated at 30% to 40%. In this cohort, 36% of our patients were classified as steroid resistant. We observed a response to CNI in 88% of these patients. This group of patients received a rescue CNI approach combined with low-dose corticosteroids, yet the cumulative prednisone dose was the highest among those in the 3 treatment groups. Treatment response was higher than those reported for corticosteroid-resistant patients, which have been estimated between 48% and 83%.[@bib23], [@bib24], [@bib26], [@bib28], [@bib29] The differences may be due to different definitions of steroid-resistant disease, as we defined resistance after 12 weeks of high-dose corticosteroid treatment, whereas others suggest waiting up to 16 weeks. It has not been studied whether a CNI-first approach may benefit patients deemed to be steroid resistant; however, predictors of steroid resistance have not been completely defined, and it is therefore difficult to predict treatment resistance in advance.

Relapse after CNI suspension has been a major hurdle preventing first-line CNI use. The incidence of relapse has been reported to be between 53% and 78% of patients once CNI inhibitors are suspended in steroid-resistant patients.[@bib8], [@bib22], [@bib23], [@bib26], [@bib28] We observed a similar relapse rate between patients treated with a prolonged course of high-dose corticosteroids and those with a CNI-first approach.

Five-year progression to ESRD has been reported in 20% to 30% of patients.[@bib6], [@bib8], [@bib11], [@bib12], [@bib13], [@bib22], [@bib25], [@bib27], [@bib30] Those who respond to treatment are less likely to progress compared to those without response or without treatment.[@bib6], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib15], [@bib27] In this study, none of the patients who responded to treatment progressed to ESRD, and this constituted an independent renal survival predictor. Although there were no differences in progression to ESRD between the high-dose prednisone and the first-line CNI groups, a numerically higher percentage of patients in the CNI-first group progressed to ESRD. A possible impact of a first-line CNI approach in preventing ESRD progression has been reported by Laurin *et al.*[@bib15] in 90 patients treated with a CNI-first approach (HR = 0.42, 95% CI = 0.15−1.18). However, a larger, long-term study is required to fully address the effect of CNI-first treatment on hard renal outcomes.

As it is not our local practice, a CNI approach without steroids was not evaluated in this study. As we reported, even the CNI-first combined with low-dose prednisone group had a median 2.5-g cumulative prednisone dose, and adverse events attributable to corticosteroid use were still observed. An exploratory study is currently underway to address this approach (AURONA trial, [NCT03598036](NCT03598036){#intref0010}).

Finally, as previously reported, the best independent predictors for long-term prognosis were the grade of proteinuria at presentation, the chronicity score observed in the diagnostic biopsy (which includes the percentage of glomerular sclerosis, tubular atrophy, and interstitial fibrosis), and the patient's response to therapy.

This study has limitations. Due to its retrospective nature and even when baseline characteristics were similar, a time bias cannot be excluded, as patients with the CNI-approach were treated in the most recent years. The effect of supportive therapies such as arterial pressure control, renin−angiotensin−aldosterone system blockade, and lipid control were not completely assessed and controlled for. As previously mentioned, the number of patients was small for determining hard renal endpoints. The follow-up was close to 5 years, which may limit its power to determine long-term prognosis, especially for the CNI groups in whom prolonged CNI toxicity may be of concern.

In conclusion, a first-line CNI plus low-dose prednisone approach in FSGS reduces corticosteroid exposure with therapy response rates similar to those associated with the currently recommended high-dose corticosteroid regimen. However, long-term preservation of renal function with this approach still remains to be addressed. These findings justify a randomized clinical trial to formally test this hypothesis.
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[^1]: CNI, calcineurin inhibitor; GFR, glomerular filtration rate estimated from the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.

[^2]: Protein-to-creatinine ratio at CNI start in the rescue CNI group represents the proteinuria after steroid treatment when the definition for resistance disease was met.

[^3]: CNI, calcineurin inhibitor; NOS, not otherwise specified variant.

[^4]: Avg, average; CNI, calcineurin inhibitor; RAAS, renin−angiotensin−aldosterone system.

[^5]: CI, confidence interval; HR, hazard ratio; Ref, reference.

[^6]: GI, gastrointestinal.

[^7]: Psychiatric symptoms included depression or anxiety requiring pharmacological intervention.
